TIDMLID
RNS Number : 8811L
LiDCO Group Plc
05 May 2020
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014
(MAR)
LiDCO Group Plc
("LiDCO" or the "Company")
Hemodynamic management in COVID-19 patients and Q1 sales
update
LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring
solutions, welcomes the recent educational webinar from the
European Society of Intensive Care Medicine ('ESICEM') regarding
hemodynamic management in COVID-19 patients. The panel consisted of
four international experts who discussed current World Health
Organisation COVID-19 treatment guidelines and explored the patient
benefits of using advanced hemodynamic monitoring in such
treatment.
During the discussions, Senior Consultant Antonio Messina at
Humanitas Hospital, Italy discussed the frontline strategies for
treating COVID-19 patients and the importance of managing these
ventilated patients' physiology with functional hemodynamic tests.
During Dr Messina's speech he called out the importance of using a
combination of a ventilator and a hemodynamic monitor to perform an
end expiratory occlusion test ('EEOT') to assess the patient's
fluid status.
This point was reinforced by Professor Jacques Duranteau, Head
of Anaesthesia and Critical Care at Bicetre hospital, Paris, who
referenced the need to employ a conservative fluid strategy and
discussed the use of another ventilator-associated method, the
tidal volume challenge ('TVC'), as a means to assess a patient's
fluid status to prevent giving COVID-19 patients any excess
fluid.
To perform these tests requires a precise measurement of the
patient's advanced hemodynamic parameters. The LiDCO monitor is
able to meet this need to measure these small changes over a short
period of time and is the only monitor on the market to have both
the EEOT and TVC as in-built guided clinical protocols.
As previously announced in LiDCO's Full-Year Results release in
April 2020, the Company has seen a strong lift in demand for its
hemodynamic monitoring systems due to COVID-19. Over 200 monitors
have been sold, predominately in the UK, in the first three months
of the financial year compared with 219 sold in the whole of
previous financial year. LiDCO has been able to supply the monitors
to ICU units around the world where patients with the most acute
symptoms of COVID-19 are being treated.
LiDCO sales in Q1 of this year (three months ended 30 April
2020) were GBP4.4m up 179% on the corresponding period last year.
As expected, Q1 sales have therefore already significantly exceeded
the total sales of GBP3.5m the Company achieved in H1 last year (6
months to 31 July 2019).
To listen to the ESICEM webinar click here:
https://bit.ly/2VDerOI
To find out more information about EEOT and TVC click here:
http://www.lidco.com/what-are-preload-responsive-ventilator-tests/
Matt Sassone, CEO of LiDCO, said: "This ESICEM webinar has
highlighted two key measurements to assist in the treatment of
COVID-19 patients, the end expiratory occlusion test (EEOT) and
tidal volume challenge (TVC), which LiDCO's technology already has
in-built. This demonstrates once again the core benefits of our
technology in the critical care environment and our technology
leadership in the advanced hemodynamic monitoring market. I am
proud of how our team met the challenge of a substantial surge in
orders in Q1, thereby doing our part to help hospitals and patients
affected by Covid-19."
For further information, please contact:
LiDCO Group Plc www.lidco.com
Matt Sassone (CEO) Tel: +44 (0)20 7749 1500
Tim Hall (CFO)
N+1 Singer Tel: +44 (0)20 7496 3172
Aubrey Powell, George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About LiDCO Group Plc ( www.lidco.com )
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
Increasingly clinical studies have shown that the optimisation
of patients' hemodynamic status in high risk patients produces
better outcomes and reduced hospital stay. LiDCO's computer-based
technology, developed originally at St Thomas' Hospital in London,
has been shown to significantly reduce morbidity and complications,
length of stay and overall costs associated with major surgery.
In critical care, LiDCO's products have various in-built guided
clinical protocols such as an end expiratory occlusion test (EEOT)
and a tidal volume challenge (TVC), as a means to assess a
patient's fluid status. These methods have been referenced by key
opinion leaders as an important part of the treatment pathway for
ventilated patients with the Covid-19 coronavirus in critical
care.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus : a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid : a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview : an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS (TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network :
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDEAXSLEEDEEFA
(END) Dow Jones Newswires
May 05, 2020 05:21 ET (09:21 GMT)
Lidco (LSE:LID)
Historical Stock Chart
From Apr 2024 to May 2024
Lidco (LSE:LID)
Historical Stock Chart
From May 2023 to May 2024